- AttorneyOne.com – Finding An Attorney Online, Just Got Easier

After completion of the evaluation of a report of a patient who died after the first dose of multiple sclerosis drug Gilenya (fingolimod) the US FDA could not definitively conclude that Gilenya was related to any of the deaths. Nevertheless the agency remains concerned about the cardiovascular effects of Gilenya after the first dose. Background [...]

FDA updates neurology, internal medicine healthcare professionals and the public of the seizure risk in patients with multiple sclerosis starting Ampyra (dalfampridine). The drug label is updated to clarify recommendations. Background of Ampyra (dalfampridine) Ampyra (dalfampridine), by Acorda, is approved to be used for the improvement of walking in patients with multiple sclerosis. Higher blood [...]

In addressing the medical fraternity, particularly neurologists and gastroenterologists, the FDA has issued an alert on the newly posed medical risks associated with Tysabri, Natalizumab. Background of Tysabri, Natalizumab The drug Tysabri (Natalizumab) falls under the category of drugs known as immunomodulators. Its working mechanism is simply in hindering various immune system cells from harming [...]

The reported case of an MS patient (Multiple Sclerosis) was received by the FDA, whereby the patient passed away in under 24 hrs after getting their first dosage of the drug Gilenya also known as Fingolimod. In light of that, neurologists, other healthcare professionals as well as patients have been informed to be on the [...]